Another drug study flops at AstraZeneca as CEO braces for bumpy turnaround

John Carroll In an interview with Reuters yesterday, CEO Pascal Soriot warned that turning around AstraZeneca is going to require a lengthy rebuilding effort. FierceBiotech News

AstraZeneca homes in on new HQ and research site in Cambridge

Tracy Staton Over the next three years the pharma company plans to build a $ 500 million complex on an 11-acre site at the Cambridge BioMedical Campus. FiercePharma News

AstraZeneca picks Cambridge site as ground zero for R&D reinvention

John Carroll Over the next three years the pharma company plans to build a $ 500 million complex on its new campus that will house its U.K. operations for biologics and small molecule ...

AstraZeneca to Bid With Takeda for Israeli Biotech Incubator

barbara.lempert BRIEF: AstraZeneca to bid with Takeda for Israeli biotech incubator TEL AVIV, Israel, June 11, 2013–UK pharmaceutical company AstraZeneca plc (LSE:AZN) is the ...

Top AstraZeneca exec bows out to helm a biotech

John Carroll AstraZeneca's announcement early this year that Peter Greenleaf would be "promoted" from the head of MedImmune to the top job in the company's big Latin ...

New deal part of Soriot’s revised strategy to energize AstraZeneca

Eric Palmer AstraZeneca's first-quarter earnings report was a stark indication of why its new CEO Pascal Soriot is scrambling to buy some new drugs the company can lean on. FiercePharma ...

AstraZeneca bags another PhIII therapy in $1.15B Pearl buyout

John Carroll The Pearl Therapeutics buyout gives AstraZeneca's late-stage development director Briggs Morrison a Phase III respiratory therapy just days after the pharma giant was ...

AstraZeneca to take $140M hit for another R&D failure

Tracy Staton Embattled AstraZeneca just can't catch a break. The pharma giant scrapped its development plans for the rheumatoid arthritis treatment fostamatinib, planning to take ...

AstraZeneca tosses another PhIII failure onto the scrap heap

John Carroll AstraZeneca just can't catch a break. After looking over lackluster late-stage results for its rheumatoid arthritis drug fostamatinib, the pharma giant has opted to ...

AstraZeneca gets mixed results in Nexium patent fight with Hanmi

Eric Palmer AstraZeneca has gotten mixed results in a lawsuit agreement as it continues to try to hold generics at bay in the U.S. for its blockbuster stomach drug Nexium. It said today ...

Bristol-Myers, AstraZeneca win turnabout at NICE for Forxiga

Tracy Staton Bristol-Myers Squibb and AstraZeneca persuaded the U.K.'s cost-effectiveness agency to make an about-face on their new diabetes drug Forxiga. FiercePharma News

Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca

barbara.lempert NEW YORK, May 28, 2013 /PRNewswire/ — Omthera Pharmaceuticals and AstraZeneca announced today that the companies entered into a merger agreement under which AstraZeneca ...
Page 7 of 9« First...56789
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS